Spravato® is an FDA-approved breakthrough treatment for treatment resistant major depressive disorder (TRD) in adults. It is an intranasal medicine, prescribed along with an oral antidepressant.

If you’re battling depression and have found no relief from two or more antidepressants during your current episode, consult with your doctor or arrange an evaluation with us to explore if Spravato could be a suitable option for you.

Spravato, also referred to as intranasal esketamine, is FDA-approved and generally covered by insurance, making it an accessible treatment for those with coverage. It must be administered by a qualified provider in a certified medical setting where patients can be closely monitored.

How does SPRAVATO® work?

Spravato is developed to treat depression by antagonizing the NMDA glutamate receptor, similar to ketamine. This action may promote the formation of new neural connections and restore neural plasticity, often improving symptoms within days instead of weeks, unlike traditional antidepressants.

Before prescribing Spravato, you'll have a consultation to review your medical history and previous depression treatments. Some medical conditions may contraindicate its use, so this review is crucial.

What happens during SPRAVATO® treatment?

Each Spravato treatment session lasts two hours in a monitored, private, and comfortable setting.

Spravato can have side effects, such as feeling disconnected, dizzy, or sleepy, but 99% of these resolve before leaving the office. Patients cannot drive after treatment and must arrange for a ride home.

The initial treatment phase involves twice-weekly visits for four weeks. If the response is satisfactory, patients move to a maintenance phase with once-weekly treatments for four weeks, then either weekly or biweekly, depending on their response.

Spravato has proven safe and effective in preventing relapse, with over five years of data and more than 800,000 treatments.

SPRAVATO® Clinical Study

Adults with treatment-resistant depression who were part of a clinical study were given either a nasal esketamine spray or a placebo spray. Those who added esketamine, the active ingredient in SPRAVATO®, to their oral antidepressant experienced a greater reduction of depressive symptoms at four weeks compared to those who received placebo plus an oral antidepressant. (Based on an overall score on a standardized rating scale.)

  • In a short-term study, more patients using SPRAVATO® plus oral antidepressant demonstrated rapid and superior reduction in depressive symptoms at four weeks compared to those who received placebo plus an oral antidepressant

  • Most of the reduction in depressive symptoms was seen at 24 hours

    Between 24 hours and four weeks, both groups continued to improve; the difference in improvement between the groups remained but did not appear to increase through four weeks

  • The trial compared patients who stayed on SPRAVATO® and oral antidepressant vs placebo and oral antidepressant long-term

  • Patients who stayed on SPRAVATO® were less likely to experience a return in depressive symptoms (known as relapse)

If two or more oral antidepressants haven’t worked for you, ask your doctor if adding SPRAVATO® may be able to help.

Start your journey to feeling better and living well.

We know that dealing with depression is tough and complex, but you're not alone. Reach out to us today, and together we'll work towards a healthier, happier life.